Clinical trial
Study to Evaluate a 13-valent Pneumococcal Conjugate Vaccine in Infants
NCT00366548 · Wyeth is now a wholly owned subsidiary of Pfizer, Industry · Completed
Key facts
| NCT number | NCT00366548 |
|---|---|
| Title | Study to Evaluate a 13-valent Pneumococcal Conjugate Vaccine in Infants |
| Official title | A Phase 3, Randomized, Double-blind Trial Evaluating the Safety, Tolerability, and Immunogenicity of a 13-valent Pneumococcal Conjugate Vaccine Manufactured With and Without Polysorbate 80 in Healthy Infants Given in a 2-, 3-, 4-, and 12-Month Schedule With Routine Pediatric Vaccinations |
| Lead sponsor | Wyeth is now a wholly owned subsidiary of Pfizer, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Vaccines, Pneumococcal |
| Intervention type | Biological |
| Interventions | 13 valent pneumococcal conjugate vaccine with Polysorbate 80, 13 valent pneumococcal conjugate vaccine without Polysorbate 80 |
| Enrollment | 500 |
| Start date | Nov 1, 2006 |
| Primary completion | Jun 1, 2008 |
| Completion | Jun 1, 2008 |
| First posted | Aug 21, 2006 |
| Last update posted | Aug 15, 2012 |
| Countries | Poland |
At a glance
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: